Login to Your Account



Hospira Chalks up First EU Biosimilar Antibody Approval

By Cormac Sheridan
Staff Writer

Wednesday, September 11, 2013
Hospira Inc. has reached a major milestone in the development of the biosimilar drugs market by gaining formal European Commission approval for Europe’s first biosimilar monoclonal antibody, Inflectra (infliximab), which is based on the blockbuster TNF-alpha inhibitor Remicade (infliximab). It represents the first major dent in the armor of the biotechnology industry’s most valuable franchise.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription